(Q37196716)

18 August 2017

1 reference

title

Receptor-directed therapy of T-cell leukemias and lymphomas (English)

1 reference

18 August 2017

2

Thomas A Waldmann

1 reference

18 August 2017

John C Morris

1

1 reference

18 August 2017

John E Janik

series ordinal

3

1 reference

18 August 2017

publication date

1 April 2008

1 reference

Journal of Immunotoxicology

18 August 2017

published in

1 reference

18 August 2017

volume

5

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

235-248

1 reference

Non-Hodgkin's lymphoma of the sinonasal tract. A clinicopathologic and immunophenotypic study of 120 cases.

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Differential effects of IL-2 and IL-15 on expression of IL-2 receptor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of IL15RA and IL2RA genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Interleukin (IL) 15/IL-T production by the adult T-cell leukemia cell line HuT-102 is associated with a human T-cell lymphotrophic virus type I region /IL-15 fusion message that lacks many upstream AUGs that normally attenuates IL-15 mRNA translatio

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

CD3-specific antibody-induced active tolerance: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

How the T cell receptor sees antigen--a structural view

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Molecular biology and pathogenesis of the human T-cell leukaemia/lymphotropic virus Type-1 (HTLV-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

NK cell recovery, chimerism, function, and recognition in recipients of haploidentical hematopoietic cell transplantation following nonmyeloablative conditioning using a humanized anti-CD2 mAb, Medi-507.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Monoclonal Antibodies Defining Distinctive Human T Cell Surface Antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

T cell subsets defined by expression of Lyt-1,2,3 and Thy-1 antigens. Two-parameter immunofluorescence and cytotoxicity analysis with monoclonal antibodies modifies current views

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

HTLV-positive and -negative T-cell lymphomas. Morphological and immunohistochemical differences between European and HTLV-positive Japanese T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Human antibodies from transgenic animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Sézary syndrome and related variants of classic cutaneous T-cell lymphoma. A descriptive and prognostic clinicopathologic study of 29 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Adult T-cell leukaemia/lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Interleukin-15: a new cytokine target for the treatment of inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Anaplastic Large Cell Lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

The structural biology of CD2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

T-cell large granular leukemia and related proliferations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Prevalence of HTLV-I-associated T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

A humanized antibody that binds to the interleukin 2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

CD5, an important regulator of lymphocyte selection and immune tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Alemtuzumab in CLL and other lymphoid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

T cell growth factor receptors. Quantitation, specificity, and biological relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Antigens involved in mouse cytolytic T-lymphocyte (CTL)-mediated killing: functional screening and topographic relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: pathogenic implications and a rationale for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Effect of anti-IL-2Ralpha antibody on IL-2-induced Jak/STAT signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Primary structure of CD52.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Characterization of the interleukin 2 receptor beta chain using three distinct monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Denileukin diftitox as novel targeted therapy for lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

SELECTIVE DELETION OF ANTIGEN-SPECIFIC, ACTIVATED T CELLS BY A HUMANIZED MAB TO CD2 (MEDI-507) IS MEDIATED BY NK CELLS

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802129661

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group

21 January 2018

1 reference

12 December 2020

A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group

1 reference

12 December 2020

Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma

1 reference

12 December 2020

Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells

1 reference

12 December 2020

Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: a randomized multicenter trial by the EBMT Chroni

1 reference

12 December 2020

Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement

1 reference

12 December 2020

Activation of naive and memory T cells by interleukin-15.

1 reference

12 December 2020

CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features

1 reference

12 December 2020

Frequent expression of CD3 epsilon in CD3 (Leu 4)-negative nasal T-cell lymphomas

1 reference

12 December 2020

Transformed mycosis fungoides: clinicopathological features and outcome

1 reference

12 December 2020

IL-15 an immunoregulatory and anti-cancer cytokine. Recent advances.

1 reference

12 December 2020

CD5 signal transduction: positive or negative modulation of antigen receptor signaling

1 reference

12 December 2020

Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice

1 reference

12 December 2020

A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma

1 reference

12 December 2020

Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac.

1 reference

12 December 2020

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

1 reference

12 December 2020

High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS

1 reference

12 December 2020

Coeliac disease and malignancy

1 reference

12 December 2020

Detailed phenotypic analysis of B-cell lymphoma using a panel of antibodies reactive in routinely fixed wax-embedded tissue

1 reference

12 December 2020

Production and characterization of a monoclonal antibody that binds Reed-Sternberg cells.

1 reference

12 December 2020

IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction

1 reference

12 December 2020

Functional effects of CD30 on a large granular lymphoma cell line, YT. Inhibition of cytotoxicity, regulation of CD28 and IL-2R, and induction of homotypic aggregation.

1 reference

12 December 2020

Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides

1 reference

12 December 2020

A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease.

1 reference

12 December 2020

Clinical and immunological studies in advanced cancer patients sequentially treated with anti CD3 monoclonal antibody (OKT3) and interleukin-2

1 reference

12 December 2020

Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Results of two phase II studies. The CD5 Plus Rheumatoid Arthritis Investigators Group

1 reference

12 December 2020

Diphtheria toxin fusion proteins

1 reference

12 December 2020

Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody

1 reference

12 December 2020

CD122 (interleukin-2 receptor beta subunit).

1 reference

12 December 2020

Humanized antibody directed to the IL-2 receptor beta-chain prolongs primate cardiac allograft survival

1 reference

12 December 2020

The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia.

1 reference

12 December 2020

The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma

1 reference

12 December 2020

Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody

1 reference

12 December 2020

Expression of interleukin-2R alpha and interleukin-2R beta in Hodgkin's disease

1 reference

12 December 2020

Bexarotene ligand pharmaceuticals.

1 reference

12 December 2020

Therapy with OKT3 monoclonal antibody in refractory T cell acute lymphoblastic leukemia induces interleukin-2 responsiveness

1 reference

12 December 2020

Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas

1 reference

12 December 2020

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project

1 reference

12 December 2020

A structural view of CD4 and CD8.

1 reference

12 December 2020

Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma

1 reference

12 December 2020

CD2 regulates the positive selection and function of antigen-specific CD4- CD8+ T cells

1 reference

12 December 2020

Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA).

1 reference

12 December 2020

A critical role for CD2 in both thymic selection events and mature T cell function

1 reference

12 December 2020

Induction immunosuppression

1 reference

12 December 2020

Biology of the interleukin-2 receptor

1 reference

12 December 2020

IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2.

1 reference

12 December 2020

1 reference

12 December 2020

Infectious toxicity using alemtuzumab.

1 reference

12 December 2020

The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies.

1 reference

12 December 2020

A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells

1 reference

12 December 2020

The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease

1 reference

12 December 2020

A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies

1 reference

12 December 2020

Biophysical characterization of a recombinant soluble interleukin 2 receptor (Tac). Evidence for a monomeric structure

1 reference

12 December 2020

Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation

1 reference

12 December 2020

Monoclonal antibodies in the diagnosis of Hodgkin's disease. The search for a rational panel.

1 reference

12 December 2020

Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study

1 reference

12 December 2020

Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin

1 reference

12 December 2020

Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H

1 reference

12 December 2020

A monoclonal antibody 7G7/B6, binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-Tac

1 reference

12 December 2020

CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy.

1 reference

12 December 2020

Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia

1 reference

12 December 2020

Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases

1 reference

12 December 2020

Phenotypic expression of Hodgkin's and Reed-Sternberg cells in Hodgkin's disease

1 reference

12 December 2020

Complementary roles for CD2 and LFA-1 adhesion pathways during T cell activation

1 reference

12 December 2020

Humanized Mik beta 1, a humanized antibody to the IL-2 receptor beta-chain that acts synergistically with humanized anti-TAC.

1 reference

12 December 2020

Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice.

1 reference

12 December 2020

A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells

1 reference

12 December 2020

Internalization and intracellular fate of anti-CD5 monoclonal antibody and anti-CD5 ricin A-chain immunotoxin in human leukemic T cells.

1 reference

12 December 2020

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

1 reference

12 December 2020

10.1080/15476910802129661

Identifiers

DOI

1 reference

18 August 2017

0 references

1 reference